Cover Image
市場調查報告書

基因重組第八凝血因子的中國市場

Investigation Report on China Recombinant Factor VIII Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332764
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
基因重組第八凝血因子的中國市場 Investigation Report on China Recombinant Factor VIII Market, 2010-2019
出版日期: 2015年06月11日 內容資訊: 英文 30 Pages
簡介

基因重組第八凝血因子在中國市場推出以來,其銷售量急速上升,2009年不到600萬人民幣的銷售量,到2014年已達到9378萬人民幣的規模。

本報告提供中國的基因重組第八凝血因子市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 基因重組第八凝血因子的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國基因重組第八凝血因子的市場簡介

  • 基因重組第八凝血因子的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國基因重組第八凝血因子銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國基因重組第八凝血因子的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國基因重組第八凝血因子的劑型的相關調查

  • Market 劑型別市場佔有率:以銷售額為準
  • Market 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的基因重組第八凝血因子的標準價格

  • Baxter Bioscience Manufacturing (SW) (Advate)
  • Wyeth Farma S.A.(SP) (Xyntha)
  • Bayer

第7章 中國市場中基因重組第八凝血因子的主要製藥公司

  • Bayer
  • Baxter Bioscience Manufacturing
  • Wyeth Farma S.A.

第8章 中國基因重組第八凝血因子的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506205

Hemophilia is a hereditary bleeding disorder caused by a lack of clotting factor VIII or IX, though not rare, which affects mostly males. Hemophilia A (clotting factor VIII deficiency) is the most common form of the disorder. The number of the cases of hemophilia is about over 0.4 million around the world while that in China is about 0.06-0.1 million, among which 80% lack clotting factor VIII while over half are in severe conditions.

Injecting clotting factor might be the only effective way to treat hemophilia. Recombinant factor VIII (Kogenate Bayer) made by Bayer was approved by FDA and EMEA in 2000 to be used in many countries. In developed countries, the drugs for the prevention and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor VIII too.

After entering China, recombinant factor VIII develops fast with annual sales value rising from less than CNY 6 million in 2009 to CNY 93.78 million in 2014 and CAGR reaching up to 76.8% during 2009-2014. Currently, recombinant factor VIII in the Chinese market are all imported drugs. They mainly come from the following three companies: Baxter Bioscience Manufacturing (SW), Wyeth Farma S.A. (SP) and Bayer (the US), among which Bayer (the US) has the largest market share of 57.40% by sales value in 2014.

As hemophiliacs' ability to pay for medical treatment keeps increasing due to economic development, the market size of recombinant factor VIII in China is expected to keep expanding.

Readers can get at least the following information from this report:

  • sales status of recombinant factor VIII in China
  • price of recombinant factor VIII in Chinese market
  • major manufacturers of recombinant factor VIII in Chinese market
  • share of dosage forms of recombinant factor VIII in China
  • market outlook of recombinant factor VIII in China

The author suggests the following groups of people purchase this report:

  • manufacturers of blood products
  • investors/ research institutions interested in China blood products market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Recombinant Factor VIII

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Recombinant Factor VIII in China

  • 2.1. Patent and Approval Status of Recombinant Factor VIII in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Recombinant Factor VIII in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Recombinant Factor VIII in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Recombinant Factor VIII in China, 2010-2014

  • 5.1. Market Share of Different Dosage Forms by Sales Value
  • 5.2. Market Share of Different Dosage Forms by Sales Volume

6. Reference Price of Recombinant Factor VIII in Chinese Hospitals in 2014

  • 6.1. Baxter Bioscience Manufacturing (SW) (Trade Name: Advate)
  • 6.2. Wyeth Farma S.A.(SP) (Trade Name: Xyntha)
  • 6.3. Bayer

7. Major Manufacturers of Recombinant Factor VIII in Chinese Market, 2010-2014

  • 7.1. Bayer
  • 7.2. Baxter Bioscience Manufacturing
  • 7.3. Wyeth Farma S.A.

8. Market Outlook of Recombinant Factor VIII in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Recombinant Factor VIII in China
  • Chart sSales Status of Recombinant Factor VIII in China
  • Chart Sales Value of Recombinant Factor VIII in China, 2010-2014
  • Chart Sales Value of Recombinant Factor VIII in Some Regions in China, 2010-2014
  • Chart Sales Volume of Recombinant Factor VIII in China, 2010-2014
  • Chart Sales Volume of Recombinant Factor VIII in Some Regions in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Recombinant Factor VIII for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Recombinant Factor VIII Made by Bayer (the US) in China, 2010-2014
  • Chart Sales Value and Market Share of Recombinant Factor VIII Made by Baxter BioScience(SW) in China, 2010-2014
  • Chart Sales Value and Market Share of Recombinant Factor VIII Made by Wyeth(SP) in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Recombinant Factor VIII for Sales Volume in China, 2010-2014
  • Chart Sales Volume and Market Share of Recombinant Factor VIII Made by Bayer (the US) in China, 2010-2014
  • Chart Price of Recombinant Factor VIII Made by Baxter Bioscience Manufacturing (SW) in Some Chinese Cities in 2014
  • Chart Price of Recombinant Factor VIII Made by Wyeth Farma S.A.(SP) in Some Chinese Cities in 2014
  • Chart Price of Recombinant Factor VIII Made by Bayer (the US) in Some Chinese Cities in 2014
Back to Top